A Bench-to-Bedside Approach to Overcome Recurrence in PDAC
Poor prognosis and drug resistance seen in pancreatic ductal adenocarcinoma (PDAC) is related to the activity of a tumor stem cell population that helps the tumor to regenerate after surgery or chemotherapy. The biology of these tumor stem cells remains poorly characterized, hampering the development of better treatment options.
In this presentation, Dr. Carles Barceló discusses the mechanisms of oncogenic addiction and resistance to adjuvant treatment seen in PDAC using patient-derived organoids. In addition, he also discusses his work on SARS-CoV-2 infection modeling using human airway organoid models.
This presentation was part of the live webinar on “Organoid Models for Studying Pancreatic Diseases”, hosted by STEMCELL Technologies on Tuesday, May 30, 2023.
In this presentation, Dr. Carles Barceló discusses the mechanisms of oncogenic addiction and resistance to adjuvant treatment seen in PDAC using patient-derived organoids. In addition, he also discusses his work on SARS-CoV-2 infection modeling using human airway organoid models.
This presentation was part of the live webinar on “Organoid Models for Studying Pancreatic Diseases”, hosted by STEMCELL Technologies on Tuesday, May 30, 2023.
Publish Date:
July 07, 2023
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.